VOLITIONRX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7869 USD | +4.92% |
|
+6.92% | +9.75% |
| May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 26 | VolitionRx Limited Announces Board Changes | CI |
Presenter SpeechAdam Lowensteiner (Analysts)Hello, everyone, and thank you for -- all for join...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7869
USD
Average target price
3.725
USD
Spread / Average Target
+373.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.75% | 64.61M | |
| -4.81% | 3.15B | |
| +31.37% | 2.99B | |
| -14.73% | 2.15B | |
| -14.39% | 1.8B | |
| +70.99% | 1.49B | |
| +23.17% | 770M | |
| -2.18% | 762M | |
| -20.41% | 575M | |
| +3.18% | 308M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- Transcript : VolitionRx Limited Presents at Lytham Partners Spring 2021 Investor Conference, Mar-30-2021 12
